Back to List View Graph View

Cyclin-dependent kinase 4/6 inhibitors

Cyclin-dependent kinase 4/6 inhibitors are a class of targeted anticancer therapies that block the activity of Cdk4 and CDK6, key regulators of cell-cycle progression from the G1 phase to the S phase.

Where the papers sit

8 papers from the last 6 months study cyclin-dependent kinase 4/6 inhibitors directly · updated from PubMed 12 Nov 2026

Study type 0 clinical trials · 4 observational · 2 preclinical · 2 unclassified

Themes one subject · 1 new direction

Those 8 are all about one subject.

  • CDK4/6 Treatment Outcomes

    Treatment research is broadening beyond response rates toward individualized management of CDK4/6 inhibitor therapy. Biomarkers such as SUV39H2 exon skipping and LINC01871 may clarify resistance or sensitivity, while machine-learning and landmark models aim to predict survival and guide sequencing. Toxicity-driven treatment modification, healthcare costs, and first- versus second-line choices remain central clinical constraints. Immune responses and subtype-specific vulnerabilities suggest potential expansion beyond HR+/HER2-negative breast cancer, but validation across cancers is still needed.

    8 papers

NEW DIRECTION

CDK4/6 inhibition can function as an immune-response primer in esophageal squamous cell carcinoma

Palbociclib treatment in treatment-naive esophageal squamous cell carcinoma models showed that CDK4/6 inhibition is not limited to suppressing cell-cycle progression: in delayed responders, it caused DNA-damage accumulation and cGAS-enriched micronuclei, activated interferon-stimulated genes, and increased immune-cell infiltration in vascularized three-dimensional spheroids 42215475May. This introduces an immunomodulatory role for CDK4/6 inhibitors—potentially exposing tumors to immune attack—rather than treating them only as direct antiproliferative agents in the established breast-cancer treatment framework.

Papers

The 8 papers from the last 6 months that study cyclin-dependent kinase 4/6 inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

CDK4/6 Treatment Outcomes (8)
  1. Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science advances · 9 Oct 2026 PMID 42853938
  2. Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer. Clinical drug investigation · 28 Sept 2026 PMID 42806185
  3. Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786218
  4. LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of visualized experiments : JoVE · 9 Sept 2026 PMID 42714000
  5. Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer. Breast cancer (Tokyo, Japan) · 7 Aug 2026 PMID 42565974
  6. Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study. Breast cancer research and treatment · 31 Jul 2026 PMID 42536225
  7. Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
  8. CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475

By study type

Observational studies and case reports (4)
  1. Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer. Clinical drug investigation · 28 Sept 2026 PMID 42806185
  2. Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786218
  3. Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer. Breast cancer (Tokyo, Japan) · 7 Aug 2026 PMID 42565974
  4. Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study. Breast cancer research and treatment · 31 Jul 2026 PMID 42536225
Preclinical: animal, cell and lab studies (2)
  1. Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science advances · 9 Oct 2026 PMID 42853938
  2. LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of visualized experiments : JoVE · 9 Sept 2026 PMID 42714000
Unclassified: not yet indexed with MeSH (2)
  1. Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
  2. CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475